Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy

被引：9

作者：

Liao, Shuang-Lu ^{[1
,2
,3
]}

Yu, Miao ^{[1
,2
,3
,4
]}

Zhao, Zuo-Tao ^{[1
,2
,3
]}

Maurer, Marcus ^{[5
]}

机构：

[1] Peking Univ First Hosp, Dept Dermatol & Venerol, Beijing, Peoples R China

[2] Beijing Key Lab Mol Diag Dermatoses, Beijing, Peoples R China

[3] Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China

[4] Peking Univ, Sch Nursing, Beijing, Peoples R China

[5] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Dermatol Allergol, Berlin, Germany

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

关键词：

omalizumab; pregnancy; chronic spontaneous urticaria; wheals; angioedema;

D O I：

10.3389/fimmu.2021.652973

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Most chronic spontaneous urticaria (CSU) patients are female, and pregnancy can aggravate the disease activity of patients, but little is known about the efficacy and safety of omalizumab in pregnant CSU patients. We report two pregnant CSU patients treated with omalizumab and review the published information on omalizumab treatment during 11 pregnancies. The outcomes reported on patients with known pregnancies showed they had normal pregnancies and healthy babies as well as complete control of their CSU. The two new cases we reported support the view that omalizumab could be an effective and safe treatment option for pregnant and breastfeeding CSU patients. Further high-quality studies need to be carried out in order to obtain more information on the long-term efficacy and safety of the use of omalizumab during pregnancy in patients with chronic urticaria, including CSU.

引用

页数：4

共 50 条

[41] Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria
Keskinkaya, Zeynep
Kaya, Ozge
Mermutlu, Selda Isik
Ogretmen, Zerrin
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2024, 185 (08) : 786 - 793
[42] Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria
Belbezier, Aude
Boccon-Gibod, Isabelle
Bouillet, Laurence
EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (01) : 86 - 87
[43] How to manage omalizumab in a relapse of chronic spontaneous urticaria?
Brigido Paredes, C.
Fernandez De Alba, I
Perez, R.
Carretero, P.
Manzanedo, L.
Alloza, P.
Reinares, C.
ALLERGY, 2019, 74 : 486 - 486
[44] Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria
Costa, Celia
Caldeira, Leonor Esteves
Paulino, Marisa
Santos, Diana F.
Silva, Susana L.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2024, 185 (03) : 260 - 266
[45] Omalizumab updosing in patients with chronic spontaneous urticaria and angioedema
Denman, Sarah
Smith, Helin
Toolan, John
Ford, Kate
Wood, Phil
Arumugakani, Gururaj
Savic, Sinisa
CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1533 - 1534
[46] Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria
Koski, Renee
Kennedy, Katelin K.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : 397 - 401
[47] Concomitant treatment with omalizumab and cyclosporine for chronic spontaneous urticaria
Rosenblum, Jake D.
Nassau, Stacy
Fonacier, Luz
Mawhirt, Stephanie L.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (01) : 111 - 112
[48] OMALIZUMAB THERAPY FOR TREATMENT OF REFRACTORY CHRONIC SPONTANEOUS URTICARIA
Trivedi, Amruta
Katelaris, Constance
INTERNAL MEDICINE JOURNAL, 2019, 49 : 32 - 33
[49] Safety of omalizumab in elderly patients with chronic spontaneous urticaria
Narvaez Fernandez, E. J.
Mir Ihara, P. K.
Caballero Molina, T.
Dominguez-Ortega, J.
Cabanas Moreno, R.
Entrala Bueso, A.
ALLERGY, 2021, 76 : 234 - 234
[50] Omalizumab and treatment-resistant chronic spontaneous urticaria
Akyol, Aynur
Oktem, Ayse
Akay, Bengu Nisa
Kundakci, Nihal
Boyvat, Ayse
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2015, 49 (03): : 180 - 183

← 1 2 3 4 5 →